: Despite many initiatives rolled out by the Health Ministry, dengue cases in the country have risen by an alarming 122.6% from January to April this year.“Selangor recorded the highest number of dengue cases at 25,090 in these first four months,“ Health Minister Datuk Seri Dr Dzulkefly Ahmad revealed at a press conference after attending the ministry’s monthly assembly today.
He said prevention programmes have been rolled out by the ministry’s enforcement unit since the beginning of the year. However, Dzulkefly said dengue is a disease which is difficult to eradicate in a short time, as mosquitoes breed continuously. “We should all take responsibility to keep our homes and environments clean. If we don’t do this, there will be massive mosquito outbreaks, especially in dengue-prone areas.”
He said the ministry is prepared to initiate the use of Wolbachia-infected Aedes mosquitoes to combat dengue in outbreak-prone areas.Deputy Prime Minister Datuk Seri Dr Wan Azizah Wan Ismail was reported as saying that Wolbachia-infected Aedes mosquitoes would be released in 10 localities in the Klang Valley beginning July as part of efforts to stem the spread of dengue in hotspot areas.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US approves dengue vaccine Dengvaxia | The Malaysian InsightUS health authorities have given their approval to dengue vaccine Dengvaxia, the controversial first treatment designed to protect against the deadly mosquito-borne virus.\n\nThe Food and Drug Administration made the announcement on Wednesday.\u00a0\n\nThe vaccine can used only under certain strict conditions: only children aged between nine and 16, who have previously confirmed infections, and who live in endemic areas, may receive the dose.\n\n\u201cWhile there is no cure for dengue disease\u2026 approval is an important step toward helping to reduce the impact of this virus,\u201d said Anna Abram, a senior FDA official.\n\nThe virus is endemic in the US territories of American Samoa, Guam, Puerto Rico and the US Virgin Islands, said the FDA.\n\nDengue, which causes hemorrhagic fever, is the world's most common mosquito-borne virus and infects an estimated 390 million people in more than 120 countries each year \u2013 killing more than 25,000 of them, according to the World Health Organisation.\n\nBut Dengvaxia, produced by the French pharmaceutical firm Sanofi Pasteur, is controversial: the Philippines, which became the first country to approve it in 2016, was also the first to ban it in February this year over safety concerns.\n\nManila is also pursuing criminal charges against the company officials over the deaths of children injected with Dengvaxia.\n\nSanofi denies the charges but in 2017 admitted the vaccine was not suitable for people who had not previously been infected with the virus.\n\nDengvaxia has previously been approved in 19 countries and the European Union, which greenlit the vaccine under similar conditions to the US, though the age range was nine to 45-years-old. \u2013 AFP, May 2, 2019.
Source: msianinsight - 🏆 8. / 63 Read more »
US approves dengue vaccine Dengvaxia | The Malaysian InsightUS health authorities have given their approval to dengue vaccine Dengvaxia, the controversial first treatment designed to protect against the deadly mosquito-borne virus.\n\nThe Food and Drug Administration made the announcement on Wednesday.\u00a0\n\nThe vaccine can used only under certain strict conditions: only children aged between nine and 16, who have previously confirmed infections, and who live in endemic areas, may receive the dose.\n\n\u201cWhile there is no cure for dengue disease\u2026 approval is an important step toward helping to reduce the impact of this virus,\u201d said Anna Abram, a senior FDA official.\n\nThe virus is endemic in the US territories of American Samoa, Guam, Puerto Rico and the US Virgin Islands, said the FDA.\n\nDengue, which causes hemorrhagic fever, is the world's most common mosquito-borne virus and infects an estimated 390 million people in more than 120 countries each year \u2013 killing more than 25,000 of them, according to the World Health Organisation.\n\nBut Dengvaxia, produced by the French pharmaceutical firm Sanofi Pasteur, is controversial: the Philippines, which became the first country to approve it in 2016, was also the first to ban it in February this year over safety concerns.\n\nManila is also pursuing criminal charges against the company officials over the deaths of children injected with Dengvaxia.\n\nSanofi denies the charges but in 2017 admitted the vaccine was not suitable for people who had not previously been infected with the virus.\n\nDengvaxia has previously been approved in 19 countries and the European Union, which greenlit the vaccine under similar conditions to the US, though the age range was nine to 45-years-old. \u2013 AFP, May 2, 2019.
Source: msianinsight - 🏆 8. / 63 Read more »